# Final Announcement: "Precision medicine in drug development"

Tuesday June 4, 2019

### Allschwil (Basel)

Precision medicine aims to tailor disease prevention, diagnosis and treatment to the individual patient, based on their individual features extracted from multiple types of data (such as multi-omics, imaging, patient history, lifestyle and environmental factors).

Advances in screening platforms and the availability of big data are fueling the scientific progress in precision medicine, spanning the early stage of drug discovery all the way through translation into clinical practice. Adequate use of statistical and computational methods are critical to its successful implementation in clinics.

The Basel Biometric Section (BBS) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) are pleased to host a European scientific meeting on this relevant and far-reaching topic. The purpose is to bring together experts from the pharmaceutical industry and academia to present the current state of the art and discuss the challenges and opportunities ahead.

#### 9.00 am - 5.00 pm

Bioinformatics for precision oncology

Niko Reerenwinkel

**Laurent Essioux** 


Roche, Switzerland

ETH Zurich, Switzerland	Bioinformatics for precision oncology
<b>Stephen Senn</b> Edinburgh, UK	Precision medicine: The honeymoon is over. It's high time for tough love.
Tomasz Burzykowski IDDI & Hasselt Univ., Belgium	Generalized pairwise comparisons for precision medicine
Adam Heathfield Pfizer, UK	Valuation of Regenerative Medicine/ Advance Therapeutics (RM/ATs): Challenges and opportunities for creating a better framework
Jack Kuipers ETH Zurich, Switzerland	Mutational interactions define novel cancer subgroups: can they inform precision oncology?
Mario Ouwens Astra Zeneca, Sweden	Difficulties with network meta-analysis when starting to use PDL1 thresholds
<b>Georgina Bermann</b> Novartis, Switzerland	Cardiovascular medicine: approaches to the use of early biomarker response to identify a patient subgroup with

enhanced therapeutic benefit

Roche: statistical perspectives

Examples of personalized Healthcare at





#### Venue

Actelion Pharmaceuticals, Hegenheimermattweg 95, Allschwil, Switzerland

#### Registration

On or before 7 May 2019 Industry rate: €150.00 Academic rate: €75.00

After 7 May 2019 Industry rate: €200.00 Academic rate: €100.00

Students: a limited number of places is available free of charge, please contact
Giusi.moffa@usb.ch

Fee includes lunch & refreshments

## TO REGISTER PLEASE GO TO:

www.efspi.org

#### **Queries contact:**

EFSPI Secretariat Tel: +44 (0)1625 664549 efspi@kingstonsmith.co.uk

Note that there is only limited parking space. Public transport is recommended:
From the airport: Line 50; change to line 31 or 38 at Kannenfeldplatz, exit at Im Brühl